Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix&#3

Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecu

Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neut

Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Pass

Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers th

Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and low

US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric

Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guida

Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to

Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendatio

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf7

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy

Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) a

Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both sm

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. Whi

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock.

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PB

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plas

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  On Thursday, 930 stocks hit new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Wednesday, 340 stocks hit new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

    On Monday, 721 companies achieved new lows for the year.

  On Friday, 431 companies hit new 52-week lows.